SCHEMBL5557793

SCHEMBL5557793

COc1ccc(C[C@H]2CN(C3=Nc4ccccc4Nc4sc(C)nc43)CCN2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 8/20 0.41
DRD2 P14416 6/20 0.40
CHRM2 P08172 4/20 0.40
CHRM4 P08173 4/20 0.40
CHRM5 P08912 4/20 0.40
CHRM3 P20309 4/20 0.40
DRD1 P21728 4/20 0.40
ADRA1D P25100 4/20 0.40
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
ADRA1A P35348 4/20 0.40
HRH1 P35367 4/20 0.40
ADRA1B P35368 4/20 0.40
HTR2B P41595 4/20 0.40
ADRA2A P08913 3/20 0.40
ADRA2B P18089 3/20 0.40
ADRA2C P18825 3/20 0.40
KCNH2 Q12809 3/20 0.40
DRD4 P21917 3/20 0.40
DRD3 P35462 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5559544 0.93 CHRM1 (0.43) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5564205 0.93 CHRM1 (0.42) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5564204 0.93 CHRM1 (0.42) CHRM1DRD2CHRM2CHRM4CHRM5
SCHEMBL14365311 0.91 DRD2 (0.43) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5562577 0.91 DRD2 (0.43) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5562565 0.91 DRD2 (0.43) CHRM1DRD2CHRM2CHRM4CHRM5
SCHEMBL14364964 0.87 CHRM1 (0.40) CHRM1DRD2CHRM2CHRM4CHRM5
SCHEMBL14156771 0.86 CHRM1 (0.43) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5564017 0.86 CHRM1 (0.39) CHRM1DRD2CHRM2CHRM4CHRM5
Hydrochloric Acid SCHEMBL5564014 0.86 CHRM1 (0.39) CHRM1DRD2CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1492794-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS LILLY CO ELI (US) 2007-12-12 EP claimed
US-20050203296-A1 For therapy of psychosis and bipolar disorder ELI LILLY AND COMPANY 2005-09-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203296-A1 For therapy of psychosis and bipolar disorder DRD4, AFF4, DRD2 CHRM1 203/4885DRD2 3/4885CHRM2 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.